Search Our Site

News filed in:

"Pharma & Healthcare"

Louisiana’s ‘Netflix’ deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck

States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry. Not so in Louisiana, where a “Netflix” payment model for hepatitis C drugs has top players eager to participate. AbbVie, Gilead Sciences subsidiary Asegua Therapeutics and Merck & Co. submitted bids for the state’s... Read More »

Read More →

States across the U.S. have taken on high drug prices with new laws, proposals and Medicaid rules, many of them unpopular with the pharma industry. Not so in Louisiana, where a “Netflix” payment model for hepatitis C drugs has top players eager to participate. AbbVie, Gilead Sciences subsidiary Asegua Therapeutics and Merck & Co. submitted bids for the state’s… Read More »

[...]

Read More

Novartis gene therapy would be cost effective up to $900,000: U.S. group

An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values... Read More »

Read More →

An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values… Read More »

[...]

Read More

FDA Fell Short in Preventing Fentanyl Abuse Crisis, Report Claims

Drug makers and federal regulators dropped the ball in tracking the use of a potentially deadly fast-acting form of the synthetic opioid fentanyl, putting thousands of patients at risk of a fatal overdose, a new study claims. Transmucosal Immediate-Release Fentanyl (TIRF) drugs are approved for use in cancer patients who’ve developed tolerance against the around-the-clock... Read More »

Read More →

Drug makers and federal regulators dropped the ball in tracking the use of a potentially deadly fast-acting form of the synthetic opioid fentanyl, putting thousands of patients at risk of a fatal overdose, a new study claims. Transmucosal Immediate-Release Fentanyl (TIRF) drugs are approved for use in cancer patients who’ve developed tolerance against the around-the-clock… Read More »

[...]

Read More

Immunotherapies could change kidney cancer care, studies suggest

The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an immunotherapy — one study used pembrolizumab, or Keytruda, and... Read More »

Read More →

The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an immunotherapy — one study used pembrolizumab, or Keytruda, and… Read More »

[...]

Read More

CMS unveils CAR-T proposal, with emphasis on patient outcomes

Dive Brief: Under a proposal released Friday, Medicare would cover CAR-T cell therapies through a Centers for Medicare and Medicaid Services (CMS) pathway known as Coverage with Evidence Development. The proposal holds a mix of provisions, including that patients must be monitored for at least two years post-treatment. Hospitals administering CAR-T therapy, whether through inpatient or outpatient... Read More »

Read More →

Dive Brief: Under a proposal released Friday, Medicare would cover CAR-T cell therapies through a Centers for Medicare and Medicaid Services (CMS) pathway known as Coverage with Evidence Development. The proposal holds a mix of provisions, including that patients must be monitored for at least two years post-treatment. Hospitals administering CAR-T therapy, whether through inpatient or outpatient… Read More »

[...]

Read More

Compounded Pain Creams Ineffective for Chronic Pain

Compounded topical pain creams work no better than placebo creams and should not be used to treat chronic pain, according to a new study published in the Annals of Internal Medicine. Researchers at the Walter Reed National Military Medical Center enrolled nearly 400 people with chronic neuropathic, joint or muscle pain in the study. Some... Read More »

Read More →

Compounded topical pain creams work no better than placebo creams and should not be used to treat chronic pain, according to a new study published in the Annals of Internal Medicine. Researchers at the Walter Reed National Military Medical Center enrolled nearly 400 people with chronic neuropathic, joint or muscle pain in the study. Some… Read More »

[...]

Read More

Preventing breast cancer metastasis by killing tumor cells in their sleep

Oncology researchers have long believed that “dormant” breast cancer cells—those that have stopped dividing and are merely hiding out in the body—are unresponsive to chemotherapy. Yet those inactive cancer cells can wake up at any time and cause life-threatening metastases. Scientists at the Fred Hutchinson Cancer Research Center say they’ve figured out how to prevent... Read More »

Read More →

Oncology researchers have long believed that “dormant” breast cancer cells—those that have stopped dividing and are merely hiding out in the body—are unresponsive to chemotherapy. Yet those inactive cancer cells can wake up at any time and cause life-threatening metastases. Scientists at the Fred Hutchinson Cancer Research Center say they’ve figured out how to prevent… Read More »

[...]

Read More

Treatment for Rare Blood Clotting Disorder Shows Efficacy in Phase 3 Study

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of... Read More »

Read More →

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of… Read More »

[...]

Read More

Massachusetts Initiative Looks at Payment Plans for Novartis’ SMA Gene Therapy

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,... Read More »

Read More →

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,… Read More »

[...]

Read More

Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed... Read More »

Read More →

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed… Read More »

[...]

Read More

Page 1 of 11

Categories
Archives